Literature DB >> 3606286

Secondary hypertension in a blood pressure clinic.

A M Sinclair, C G Isles, I Brown, H Cameron, G D Murray, J W Robertson.   

Abstract

The prevalence, reversibility, and mortality of secondary hypertension among 3783 patients with moderately severe nonmalignant hypertension attending the Glasgow (Scotland) Blood Pressure Clinic were assessed. Underlying causes of hypertension were found in 297 patients (7.9%). Eighty-seven patients (2.3%) were considered to have a potentially reversible cause for their hypertension, including the oral contraceptive pill (38 patients), renovascular disease (27 patients), and primary hyperaldosteronism (ten patients), but of these only 33 patients (0.9% of total clinic population) were cured by specific intervention. Two hundred ten patients (5.6%) had irreversible renal parenchymal disease and significantly higher mortality than men and women with other causes of hypertension. Excess deaths in the renal group were attributed to renal failure (International Classification of Diseases [ICD] 580 to 589) and vascular causes (ICD 390 to 458) but not to cancer (ICD 140 to 208; 235 to 239) or other nonvascular disease. These results suggest that investigation of hypertension for an underlying cause will reveal a small number of patients with treatable disorders, of whom only a few will be cured by specific intervention, and a moderate number with irreversible disease who are at high risk of myocardial infarction and stroke.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3606286

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  40 in total

Review 1.  Evidence based management of hypertension: What to do when blood pressure is difficult to control.

Authors:  J E O'Rorke; W S Richardson
Journal:  BMJ       Date:  2001-05-19

2.  Images of pheochromocytoma in adrenal glands.

Authors:  Shaunagh McDermott; Colin J McCarthy; Michael A Blake
Journal:  Gland Surg       Date:  2015-08

Review 3.  Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review.

Authors:  Roland Därr; Matthias Kuhn; Christoph Bode; Stefan R Bornstein; Karel Pacak; Jacques W M Lenders; Graeme Eisenhofer
Journal:  Endocrine       Date:  2017-04-12       Impact factor: 3.633

Review 4.  The role of the kidney in regulating arterial blood pressure.

Authors:  Hani M Wadei; Stephen C Textor
Journal:  Nat Rev Nephrol       Date:  2012-08-28       Impact factor: 28.314

Review 5.  Screening for adrenal-endocrine hypertension: overview of accuracy and cost-effectiveness.

Authors:  Gary L Schwartz
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

6.  Pheochromocytoma in pregnancy: a case report and review of literature.

Authors:  J George; J Y L Tan
Journal:  Obstet Med       Date:  2010-06-03

Review 7.  Secondary Arterial Hypertension: From Routine Clinical Practice to Evidence in Patients with Adrenal Tumor.

Authors:  Marco Grasso; Marco Boscaro; Carla Scaroni; Filippo Ceccato
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-11-10

8.  Rapid treatment of moderate to severe hypertension using a novel protocol in a single-centre, before and after interventional study.

Authors:  Andrew N Jordan; Christine Anning; Lindsay Wilkes; Claire Ball; Nicola Pamphilon; Christopher E Clark; Nicholas G Bellenger; Angela C Shore; Andrew S P Sharp
Journal:  J Hum Hypertens       Date:  2019-10-23       Impact factor: 3.012

9.  Primary aldosteronism: difference in clinical presentation and long-term follow-up between adenoma and bilateral hyperplasia of the adrenal glands.

Authors:  T Jeck; B Weisser; T Mengden; L Erdmenger; S Grüne; W Vetter
Journal:  Clin Investig       Date:  1994-12

10.  Mesangial proliferative glomerulonephritis with aldosterone-producing adenoma.

Authors:  Masayuki Tanemoto; Michiaki Abe; Fumitoshi Satoh; Takaaki Abe; Hiroshi Satoh; Sadayoshi Ito
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.